An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker, +30

Nature

Tumor BiologyBcl-2 Family ProteinsMedicineSolid TumoursCell Death +7

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, +36

Nature Medicine

ThrombopoiesisThrombosisHematological MalignancyOncologyAntitumor Activity +9

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes, +15

Cancer Research

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert, +29

Science Translational Medicine

Cancer TherapyChemoprevention StrategyBcl-2/bcl-xl/bcl-w Inhibitor Abt-263ImmunologyPharmacotherapy +18

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

H Zhang, J Chen, Sajid Khan Tahir, +24

Cell Death and Disease

Bcl-2 family proteins are essential for platelet survival

H Zhang, Paul Nimmer, Stephen K Tahir, +13

Cell Death and Differentiation

ThrombopoiesisThrombosisBlood PlateletImmunologyHematology +6

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang, +36

ACS Medicinal Chemistry Letters

Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL

Milan Bruncko, Thorsten Oost, Barbara Belli, +19

Journal of Medicinal Chemistry

ImmunologyPharmacotherapyPharmaceutical ChemistryCompound 2Tumor Biology +17

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

Cheol‐Min Park, Milan Bruncko, Jessica Adickes, +16

Journal of Medicinal Chemistry

Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, +36

ThrombosisMolecular PharmacologyBlood PlateletNat MedMedicine +8